Baxter International vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Deerfield IL hospital medical technology (NYSE: BAX) at $10.636B 2024 revenue; Vantive kidney care sold to Carlyle $3.8B (Jan 2025), new CEO Andrew Hider (Sep 2025) competing with ICU Medical for IV solutions and infusion systems.
About
Baxter International Inc. is a Deerfield, Illinois-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BAX) as an S&P 500 component — providing hospitals, nursing homes, ambulatory surgery centers, and home healthcare settings with intravenous (IV) solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, advanced surgical equipment, and digital health solutions through approximately 38,000 employees worldwide. In fiscal year 2024, Baxter reported $10.636 billion in revenue from continuing operations with a market capitalization of approximately $15 billion. Baxter has undergone significant strategic transformation: divesting its kidney care business (Vantive) to Carlyle Group for $3.8 billion in January 2025 and its biopharma solutions business for $4.25 billion in 2023, sharpening focus on its three core segments — Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. In July 2025, Baxter appointed Andrew Hider as President and CEO (effective September 2025), bringing operational excellence expertise from his tenure as CEO of ATS (where he doubled revenues and tripled the stock price). Founded in 1931, Baxter introduced the first commercially prepared IV solutions and the first commercially-built kidney dialysis system.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.